newsfilter
← Latest News
ACCESS Newswire·

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed